Pancreatic Cancer Research

Clinical trialNAUnknown

Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer

Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer: A Prospective Single-center, Single-arm, Investigator-initiated, Open-labeled, Exploratory Clinical Trial

NCT05262452↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Outcome unknown
Phase
NA
Status
Unknown
Study type
Interventional
Start
9 August 2021
Expected end
December 2024
Enrollment
60 participants
Sites
1
Primary outcomes
2-month Tumor Response; 4-month Tumor Response; 6-month Tumor Response; Percentage of subjects that were subject to surgical resection
Sponsor
Other
Results posted
No
Last update
26 October 2022

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 19